Athira Pharma, Inc. (ATHA)
| Market Cap | 22.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -109.22M |
| Shares Out | 38.67M |
| EPS (ttm) | -2.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,716 |
| Open | 0.546 |
| Previous Close | 0.548 |
| Day's Range | 0.520 - 0.576 |
| 52-Week Range | 0.412 - 4.298 |
| Beta | 3.00 |
| Analysts | Buy |
| Price Target | 11.25 (+1,853.13%) |
| Earnings Date | Feb 20, 2025 |
About ATHA
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease dementia and... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ATHA stock is "Buy." The 12-month stock price forecast is $11.25, which is an increase of 1,853.13% from the latest price.
News
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and sl...
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by y...
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring
Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of...
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
On Wednesday, Athira Pharma, Inc. ATHA stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's dise...
Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial
Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease.
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23)
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be ...
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024
Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
Athira Pharma to Participate in Upcoming June Conferences
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer's Disease on Track for Second Half of 2024 Management to Highlight Robust Pip...
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health an...
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New Drug...
Athira Pharma to Participate in Upcoming May Conferences
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health a...
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Presentation to highlight therapeutic potential of Athira's small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and...
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's & Parkinson's Diseases at AD/PD™ 2024
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease; topline data expected in second half of 2024 On track to in...
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease and expects topline data in second half of 2024 Plans to ini...
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease
Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgo...
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative dis...
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer's disease Com...
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease
BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health a...